Search Legislation

The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening Options

Changes over time for: Section 24

 Help about opening options

Alternative versions:

Changes to legislation:

There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019, Section 24. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Amendment of Schedule 3 (particulars and documents that must accompany an application for an ethics committee opinion, a request for authorisation, a notice of amendment and a notification of the conclusion of a trial)U.K.

This section has no associated Explanatory Memorandum

24.—(1) Schedule 3 is amended as follows.

(2) In Part 1 M1, in paragraph 3(b), after “summary of product characteristics” insert “ , or equivalent document, ”.

(3) In Part 2—

(a)in paragraph 1(b), for “an EEA State”M2, substitute “the United Kingdom or a country that is included in the list referred to in regulation 3(11A)”;

(b)in paragraph 4, for “another”, substitute “ an ”;

[F1(c)in paragraph 7, after “details of any” insert “manufacturing authorisation or any”;]

(d)in paragraph 8—

[F2(i)in sub-paragraph (1), after “in accordance with” insert “regulation 43(2) or”;]

[F3(ii)for sub-paragraph (2) substitute—

(2) If an investigational medicinal product to be used in the clinical trial has been, or is to be—

(a)imported into Great Britain from a country other than Northern Ireland or imported into Northern Ireland from a country other than an EEA State, a statement from the qualified person at the disposal of the person holding the manufacturing authorisation in relation to that importation specifying—

(i)the address of any premises outside the United Kingdom at which the product was manufactured or assembled; and

(ii)the manufacturing or assembling operations performed at those premises;

(b)imported into Northern Ireland from an EEA State, a statement from the qualified person at the disposal of the person holding the authorisation referred to in Article 13 of the Directive in relation to that importation specifying—

(i)the address of any premises outside the European Economic Area at which the product was manufactured or assembled; and

(ii)the manufacturing or assembling operations performed at those premises..]

(iii)in paragraph 11(4)(a), after “summary of product characteristics” insert “ or equivalent document ”.

(4) In Part 3, in paragraph 1(b), for “an EEA State”, substitute “ the United Kingdom or a country that is included in the list referred to in regulation 3(11A) ”.

(5) In Part 4, in paragraph 1(b), for “an EEA State”, substitute “ the United Kingdom or a country that is included in the list referred to in regulation 3(11A) ”.

Textual Amendments

F1Reg. 24(3)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 8(a)

F2Reg. 24(3)(d)(i) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 8(b)

F3Reg. 24(3)(d)(ii) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 8(c)

Commencement Information

I1Reg. 24 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Marginal Citations

M1Part 1 was amended by S.I. 2008/941.

M2The words “an EEA State” were substituted by S.I. 2006/1928.

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Impact Assessments

Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:

  • Why the government is proposing to intervene;
  • The main options the government is considering, and which one is preferred;
  • How and to what extent new policies may impact on them; and,
  • The estimated costs and benefits of proposed measures.
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources